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Abstract 
Even if severe asthma (SA) accounts for 5–10% of all cases of the disease, it is currently a crucial unmet need, owing 
its difficult clinical management and its high social costs. For this reason several networks, focused on SA have been 
organized in some countries, in order to select these patients, to recognize their clinical features, to evaluate their 
adherence, to classify their biological/clinical phenotypes, to identify their eligibility to the new biologic therapies 
and to quantify the costs of the disease. Aim of the present paper is to describe the ongoing Italian Severe Asthma 
Network (SANI). Up today 49 centres have been selected, widespread on the national territory. Sharing the same 
diagnostic protocol, data regarding patients with SA will be collected and processed in a web platform. After their 
recruitment, SA patients will be followed in the long term in order to investigate the natural history of the disease. 
Besides clinical data, the cost/benefit evaluation of the new biologics will be verified as well as the search of peculiar 
biomarker(s) of the disease.
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Background
Asthma is a common disease being its prevalence world-
wide around 5–7%. Despite effective treatments and 
management guidelines, 5–10% of asthmatics suffer 
from severe asthma, characterized by frequent exacer-
bations, regular use of high dose of inhaled steroids and 
need of frequent burst of oral steroids, unscheduled vis-
its, accesses to emergency room and hospitalizations 
[1]. Though the prevalence of severe asthma is relatively 
low, it accounts for 50% of the global costs of the disease, 
being a clinical as well as social problem.
Severe asthma is an heterogeneous disease, with dif-
ferent clinical and inflammatory phenotypes [2, 3]. This 
large heterogeneity in the clinical and biological mani-
festations of severe asthma is important for prognosis, 
but mainly for selecting specific targets for pharmaco-
logic and non pharmacologic interventions, and also for 
selecting patients potentially moving from severe asthma 
to more systemic diseases [4].
Besides the pharmacological treatment, currently 
two biologics are available as add-on therapy for those 
patients: omalizumab, an anti-IgE monoclonal anti-
body, and mepolizumab, an anti-IL5 monoclonal anti-
body, approved and included in GINA Guidelines 2016 
[5]. However, several other biologics targeting differ-
ent cytokines involved in the inflammatory cascade are 
under evaluation (dupilumab—anti IL4recα-IL13, benral-
izumab—anti IL5, tralokinumab and lebrikizumab—anti 
IL13) [6–8]. These drugs will offer a powerful improve-
ment in the management of the disease but, on the other 
hand, due to their high costs, the sustainability of these 
treatments is strongly based on strict criteria of patient’s 
eligibility. Therefore the identification and the accurate 
selection of patients with SA is currently a crucial unmet 
need in the management of the disease [9].
To face up to this problem several registries collect-
ing the cases of severe asthma have been create recently 
in some countries. After the American TENOR cohort 
study [10, 11], subsequently in Europe similar registries 
were also developed in Belgium [12], in Spain [13, 14] 
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and also in Italy, though limited to the North–East ter-
ritory or related to specific research studies [15–17]. 
Possibly the most well organized registry on refractory 
asthma has been create in the United Kingdom by the 
British Thoracic Society [18–22]. Many issues have been 
addressed by these networks, such as the clinical features 
and phenotypes of severe asthma, their stability over 
time, the cost of the disease and of their comorbidity, 
the efficacy and the effectiveness of the biologic therapy 
(Table 1).
The present paper focuses on the ongoing project of an 
Italian National Registry, SANI (Severe Asthma Network 
in Italy) promoted by GINA Italy—SIAAIC (Italian Soci-
ety Allergy, Asthma and Clinical Immunology) and SIP/
IRS (Italian Respiratory Society). The aim of this network 
is to enroll patients with severe asthma, in a real life set-
ting, recruited by specialized centers, homogeneously 
placed on a database management system to follow them 
over the time.
The relevance of the real life studies is particularly 
critical in SA, where most of clinical data come from 
large controlled studies. However, as recently empha-
sized, there is a long distance between the patients 
strictly selected for clinical trials and the patients usu-
ally visited in daily routine. Randomized control trials 
are the cornerstone of the evidence based medicine as 
they are designed to evaluate the efficacy and safety of a 
particular treatment in a population under ideal condi-
tion. The aim of the real life studies to assess the real 
life efficacy of the same treatment, known as “effective-
ness” [23, 24]. Recently this gap has been clearly shown 
as regards omalizumab treatments [25].
Design and participants
The Italian asthma observatory is a web-based regis-
try encompassing demographic, clinical, functional and 
inflammatory data of severe asthmatics (SA), recruited 
by Italian Unit of Allergy and Pulmonology. The web plat-
form has been already successfully tested in a recent pre-
vious pilot study [15], and further improved by collecting 
the suggestions of SANI Scientific Committee members. 
Under a technical perspective, the platform is conceived 
in order to facilitate data entry as much as possible. Drop 
down menus are provided for most of the fields; the fol-
low-up pages are prefilled with the information included 
at baseline, available for updates only; an automatic fol-
low-up alert system is provided by email to every clini-
cian for each of the patients included. Participant centers 
have access with a code to include anonymously the data 
of patients. This step is needed to assure privacy require-
ments despite data sharing. However the matching with 
other national registries of interests (i.e. hospitalizations 
for asthma exacerbations, pharmaceutical data and so 
on) will be possible as the coding system is completely 
tracked and accessible by the platform technical staff.
The information collected will provide:
a. The collection of homogeneous clinical, functional 
and biologic data of patients with SA in a real life set-
ting.
b. The evaluation of adherence to treatment in real life.
c. The clinical eligibility of patients treated with biolog-
ics.
d. The evaluation of patients’ clinical response to each 
treatment.
Table 1 Registries on severe asthma currently available in USA and Europe
TENOR The epidemiology and natural history of asthma:outcomes and treatment regimens, BSAR Belgian Severe Asthma Registry, NEONET Italian North-East 
Omalizumab Network, ARRISA at risk register in severe asthma, BTS British Thoracic Society
Registry (reference) Country No. of centers Study population Outcomes
TENOR [8, 9] USA 283 4.756 Natural history of SA
BSAR [10] Belgium 9 350 Definition of clinical phenotypes in SA
Spanish Multi-Centers Registry [11] Spain 30 266 Omalizumab efficacy
Spanish Multi-Centers Registry [12] Spain 30 295 Omalizumab efficacy
NEONET [13] Italy 9 112 Omalizumab efficacy and safety
ARRISA [14] UK 29 Primary care practices 911 Impact of the network on exacerbation
BTS Severe Refractory Asthma Registry [15] UK 4 382 Phenotype characterization, standardized 
assessment
BTS Severe Refractory Asthma Registry [16] UK 4 349 Three years follow up
BTS Severe Refractory Asthma Registry [17] UK 4 349 Phenotype stability over time
BTS Severe Refractory Asthma Registry [18] UK 7 516 Economic analysis of SA
BTS Severe Refractory Asthma Registry [19] UK 7 808 Comorbidity due to the use of systemic steroid
Page 3 of 6Senna et al. Clin Mol Allergy  (2017) 15:9 
e. The monitoring of tolerability and safety.
f. The long-term follow up of patients with SA.
Every center to be included needs to submit an applica-
tion form in which clinical and scientific issues were eval-
uated such as personnel dedicated to asthma (specialists 
and nurses), population of asthmatics yearly treated, 
availability of lung function equipment and other clinical 
procedures, number and quality of scientific publications 
on asthma and severe asthma. For each aspect documen-
tation is required and each item is evaluated by a scor-
ing system validated within the Scientific Committee. 
The maximum score is 100 points. To be eligible every 
center has to achieve a minimum score of 75. Up to now 
all the applicants have reached the minimum threshold 
and overall 51 centers have been recruited, distributed 
throughout the Italian territory (Fig. 1).
The patient enrollment protocol has been approved by 
the Central (P.I.) Ethics Committee, and the enrollment 
in the other Centers starts upon approval of each Ethics 
Committee of reference.
Study population
Inclusion criteria are:
a. Age >12 years.
b. Diagnosis of SA according to the ERS/ATS criteria 
[1].
Fig. 1 Geographic distribution of Referral Centers currently involved in SANI project
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c. Lack of asthma control despite regular treatment 
with the combination of high dosage of inhaled corti-
costeroids (ICS) and beta 2 long acting.
Exclusion criteria have not been considered in order to 
have a realistic view of SA in real life. However, as obser-
vational studies have suggested that up to 50% of patients 
referred with severe asthma after a detailed evaluation 
do not have a refractory disease but different causes 
responsible for persistent symptoms, a detailed diagnos-
tic protocol will be shared by all participant centers. Fur-
thermore following the first visit patients will be enrolled 
after a period of 3–5  months of follow up, in order to 
exclude confounding factors such as a poor adherence 
to the treatment or the existence of exacerbating fac-
tors (passive or active smoking, occupational irritants or 
allergens etc.).
In the web registry all data collected at the enrollment 
visit as well as those recorded during the follow up visits, 
scheduled every 6 months, will be included. Data inclu-
sion of patients recruited will be task of the specialist 
who is responsible for the treatment. However, data man-
ager supervision will be scheduled for each participant 
center every 3 months.
For each participant the following information will be 
collected:
 1. Demographic data (age, sex, height, weight, BMI).
 2. Clinical features (presence of allergies and/or comor-
bidity, lung function, previous accesses to ER and/or 
hospitalizations).
 3. Asthma control in the previous month according to 
the GINA Guidelines [5] and standardized question-
naires (ACT, ACQ).
 4. Adherence to treatment.
 5. Presence of potential future risks.
 6. Concomitant regular and on demand treatments, 
Including AIT-Allergen Immunotherapy.
 7. Treatments used for comorbidities (e.g. steroids for 
nasal polyposis).
 8. Reports of previous adverse reactions to the drugs/
biologics used.
 9. Inflammatory markers (FeNO, eosinophils in the 
blood and/or in the sputum).
 10. Reasons for withdrawal from biologic treatment.
 11. Assessment of the quality of life through standard-
ized questionnaires (AQLQ) which will be drawn up 
by the patient without the support of any parents, 
nurses or physicians.
The length of the follow up for each patient is sched-
uled for 10 years.
All the information listed above will be collected both 
at baseline and at every follow-up visit. Timing and type 
of requested information represent a specific standard-
ized protocol to be followed by the participating centers 
in assessing and monitoring recruited patients. It will 
allow creating a quite homogeneous data set despite the 
real life setting.
Statistical analysis
The web application contains a section, which includes 
the most important statistics and graphs updated in 
real time for the whole network and for each single 
participant center. Results are expressed as a mean and 
standard deviation for continuous variables, as percent-
age for categorical ones. Shapiro–Wilk test will be used 
to test the normal distribution of continuous variables. 
Two-sample test of proportion will be employed to 
compare two groups for categorical data whereas two 
sample t test to compare the mean of two groups. Chi 
square test or Fisher test will be applied to assess the 
association between categorical variables. Many other 
statistical multivariate models will be implemented to 
investigate the relationships between outcome vari-
ables and predictors variables. Every statistics will be 
run in real time on the web-application via R software 
or Stata software.
The first purpose of the data collection is providing epi-
demiological end descriptive information about severe 
asthma in Italy, which is the currently the main unmet 
need. The above-mentioned statistical analysis lines are 
already included in the protocol approved by the Cen-
tral (P.I.) Ethics Committee and they allow expanding the 
research lines on our dataset. The Scientific Committee 
will evaluate any application for further analysis propos-
als, and if needed amendments to the main protocol will 
be submitted to the Ethics Committees.
Ethical issues
The observatory will be carried out according to the dec-
larations of Helsinki and Oviedo. The protocol has been 
performed according to the principles and procedures 
of the Good Clinical Practice (ICH Harmonized Tripar-
tite Guidelines for Good Clinical Practice 1996; Directive 
91/507. EEC, The Rules Governing Medical Products in 
the European Community) and in accordance with the 
Italian laws (D.L.vo n.211 del 24 Giugno 2003; D.L. n.200 
del 6 Novembre 2007; MD del 21 Dicembre 2007). SANI 
initiative is supported by several pharmaceutical com-
panies, which have been listed in the acknowledgement. 
They provide unrestricted grants and they do not have 
any role in the study design, planned analysis. In fact they 
are not having representatives in the scientific committee.
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Concluding remarks
“Precision medicine” is now the new challenge in asthma 
treatment. This approach is related to the growing evi-
dence of different asthma phenotypes and endotypes, 
which may require specific approaches to the pharma-
cologic treatments. This is particularly true for severe 
uncontrolled asthma, where new expensive biologic 
drugs will be available in the next future. Therefore, an 
accurate assessment of these patients and the collection 
of a large database in our country are compulsory for 
having a greater knowledge of this subgroup of asthmatic 
patients.
The SANI project would like to cover this gap of accu-
rate characterization of patient affected by severe uncon-
trolled asthma, in order to promote an appropriate 
assessment and therapeutic management of these com-
plex patients.
Key points
  – Severe asthma still represents an unmeet need in the 
asthma management and its epidemiologic burden as 
well as its clinical classification are still unclear.
  – In order to address these problems it is critical to select 
patients according to strict diagnostic criteria and con-
sequently to collect a large homogeneous population 
sample to evaluate.
  – Besides the clinical and economic assessment the avail-
ability of a large population of SA patients represents 
the starting point for biomarker research, aimed to 
identify in advance the potential responder and not 
responder to single biologic treatment. This finding 
will be the cornerstone for the future financial sustain-
ability of these high cost treatments [8, 9, 26].
  – Long term follow up will include monitoring of treat-
ment safety and tolerability.
  – Long term follow up will also provide possible data 
concerning the persistence of effectiveness of treat-
ment after suspension.
  –
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